There was not a significant difference between the SZ and BP groups ( P =0.802)
And the risks of combination therapy, cardiovascular strain, amplified side effects, drug interactions, additional monitoring requirements, are not trivial
To view or add a comment, sign in 4,257 followers Explore related topics Trends in Glp-1 Treatment Options Trends in Obesity Treatment Options How New Treatments Support Disease Management Advancements in Diabetes and Obesity Treatments Impact of Glp-1 Medications on Health Reasons Health Plans Restrict Obesity Drug Coverage How Policy Shapes Obesity Care Practices Policy Changes for Supporting Obesity Management
Your clinician titrates the dose gradually based on your response and tolerability
Insulin-sensitizing peptides warrant caution given Retatrutides glucose effects
It also requires careful sample preparation to prevent artifactual oxidation of GSH during extraction